GSA Capital Partners LLP Invests $740,000 in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

GSA Capital Partners LLP bought a new stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 22,493 shares of the company’s stock, valued at approximately $740,000.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Lisanti Capital Growth LLC bought a new position in Tarsus Pharmaceuticals in the third quarter valued at approximately $1,311,000. Emerald Advisers LLC bought a new position in shares of Tarsus Pharmaceuticals in the third quarter valued at $4,812,000. Harbor Capital Advisors Inc. increased its holdings in Tarsus Pharmaceuticals by 57.5% during the third quarter. Harbor Capital Advisors Inc. now owns 18,105 shares of the company’s stock worth $595,000 after buying an additional 6,612 shares during the last quarter. Emerald Mutual Fund Advisers Trust acquired a new position in Tarsus Pharmaceuticals during the third quarter worth $3,608,000. Finally, China Universal Asset Management Co. Ltd. raised its position in Tarsus Pharmaceuticals by 64.9% during the third quarter. China Universal Asset Management Co. Ltd. now owns 7,317 shares of the company’s stock worth $241,000 after acquiring an additional 2,879 shares in the last quarter. Institutional investors and hedge funds own 90.01% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently weighed in on TARS shares. Oppenheimer boosted their price objective on shares of Tarsus Pharmaceuticals from $63.00 to $65.00 and gave the stock an “outperform” rating in a research note on Thursday. The Goldman Sachs Group boosted their price target on Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the stock a “neutral” rating in a research report on Friday. Finally, William Blair upgraded Tarsus Pharmaceuticals to a “strong-buy” rating in a research note on Friday, August 30th. One research analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Tarsus Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $54.20.

Tarsus Pharmaceuticals Stock Down 3.9 %

Shares of TARS opened at $44.83 on Monday. The firm has a market cap of $1.71 billion, a P/E ratio of -11.77 and a beta of 1.00. The company has a debt-to-equity ratio of 0.30, a quick ratio of 6.99 and a current ratio of 5.42. Tarsus Pharmaceuticals, Inc. has a 52 week low of $15.60 and a 52 week high of $52.99. The firm’s 50-day simple moving average is $37.84 and its 200 day simple moving average is $32.53.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.